Trial Profile
Evaluate the safety and tolerability of hyzaar(R) (losartan 50 mg/ hydrochlorothiazide 12.5 mg) in the treatment of hypertension.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 May 2022
Price :
$35
*
At a glance
- Drugs Losartan/hydrochlorothiazide (Primary)
- Indications Essential hypertension
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Merck & Co; Merck Sharp & Dohme Corp.
- 01 Feb 2007 Status changed from recruiting.
- 05 Dec 2006 New trial record.